Measuring the outcome of clinical trials
Recent articles
Featured articles
Why don’t we have better drugs for autism?
Clinical trials for autism drugs have been plagued with problems: bad design, the wrong measures, too broad a range of participants. All that is finally starting to change.
Why don’t we have better drugs for autism?
Clinical trials for autism drugs have been plagued with problems: bad design, the wrong measures, too broad a range of participants. All that is finally starting to change.
Questions for Gahan Pandina: New tool may aid autism trials
A new ‘knowledge engine’ collects reams of behavioral and sensory data to create highly sensitive outcome measures for autism drugs.
Questions for Gahan Pandina: New tool may aid autism trials
A new ‘knowledge engine’ collects reams of behavioral and sensory data to create highly sensitive outcome measures for autism drugs.
Despite setbacks, fragile X drugs file into clinical trials
Our infographic displays efforts to develop treatments for fragile X syndrome. So far, none of them have passed muster in clinical trials.
Despite setbacks, fragile X drugs file into clinical trials
Our infographic displays efforts to develop treatments for fragile X syndrome. So far, none of them have passed muster in clinical trials.
From the archives
The innovators: How families launch their own autism studies
Some parents are starting ‘N-of-1’ studies for autism, but their efforts don’t always get taken seriously.
The innovators: How families launch their own autism studies
Some parents are starting ‘N-of-1’ studies for autism, but their efforts don’t always get taken seriously.
Questions for James McPartland: Biomarkers for better trials
A $28 million initiative aims to develop objective tools for tracking social skills in children with autism. The initiative’s leader outlines its approach.
Questions for James McPartland: Biomarkers for better trials
A $28 million initiative aims to develop objective tools for tracking social skills in children with autism. The initiative’s leader outlines its approach.
Devising spectrum of tests for different types of autism
Finding biomarkers for different forms of autism may lead to more effective treatments for each.
Devising spectrum of tests for different types of autism
Finding biomarkers for different forms of autism may lead to more effective treatments for each.
Better behavioral tests may save trials of autism treatments
Trials to test drugs for autism suffer from subjective measurements and placebo effects. Helen Tager-Flusberg outlines how to ferret out the true effects of potential autism therapies.
Better behavioral tests may save trials of autism treatments
Trials to test drugs for autism suffer from subjective measurements and placebo effects. Helen Tager-Flusberg outlines how to ferret out the true effects of potential autism therapies.
Some people in ‘failed’ drug trial for autism showed benefit
An experimental drug called arbaclofen improved autism features in about 13 percent of people who took it in a shuttered clinical trial.
Some people in ‘failed’ drug trial for autism showed benefit
An experimental drug called arbaclofen improved autism features in about 13 percent of people who took it in a shuttered clinical trial.
Questions for Eric Klann: Translating treatments for fragile X
Treatments for fragile X syndrome may be more successful if they block direct targets of the key missing protein, says Eric Klann.
Questions for Eric Klann: Translating treatments for fragile X
Treatments for fragile X syndrome may be more successful if they block direct targets of the key missing protein, says Eric Klann.
Why trials of autism treatments have a placebo problem
People with autism — and their family members — are susceptible to powerful placebo effects. Some researchers are using the problem to better understand this mystifying phenomenon.
Why trials of autism treatments have a placebo problem
People with autism — and their family members — are susceptible to powerful placebo effects. Some researchers are using the problem to better understand this mystifying phenomenon.
Questions for Elizabeth Berry-Kravis: Measuring drug effects
Drugs designed to treat fragile X syndrome have yet to show substantial benefits in people. But rather than abandon them, child neurologist Elizabeth Berry-Kravis suggests a new way to measure their effectiveness.
Questions for Elizabeth Berry-Kravis: Measuring drug effects
Drugs designed to treat fragile X syndrome have yet to show substantial benefits in people. But rather than abandon them, child neurologist Elizabeth Berry-Kravis suggests a new way to measure their effectiveness.
Better tools needed to assess clinical trials
The past few years have seen an unprecedented number of clinical trials for experimental drugs to treat autism-related disorders, most notably for fragile X syndrome. But as the trials progress, scientists are calling for better methods to measure the drugs’ effectiveness.
Better tools needed to assess clinical trials
The past few years have seen an unprecedented number of clinical trials for experimental drugs to treat autism-related disorders, most notably for fragile X syndrome. But as the trials progress, scientists are calling for better methods to measure the drugs’ effectiveness.
Explore more from The Transmitter
This paper changed my life: Stephanie Palmer on the ties between human speech and birdsong—and her ‘informal life coach’
A groundbreaking review by Allison Doupe, who was Palmer’s mentor, and Patricia Kuhl helped shape the field’s understanding of the neural and evolutionary dynamics of speech.
This paper changed my life: Stephanie Palmer on the ties between human speech and birdsong—and her ‘informal life coach’
A groundbreaking review by Allison Doupe, who was Palmer’s mentor, and Patricia Kuhl helped shape the field’s understanding of the neural and evolutionary dynamics of speech.
Restoring excitation-inhibition balance in a mouse model of autism; and more
Here is a roundup of autism-related news and research spotted around the web for the week of 17 March.
Restoring excitation-inhibition balance in a mouse model of autism; and more
Here is a roundup of autism-related news and research spotted around the web for the week of 17 March.
Lions and tigers and bears: Long-lived zoo animals offer a promising venue to study mental health and neurodegenerative disorders
These animals’ lifestyles often mirror those of people, making them a more relevant milieu than lab mice for determining how environmental factors influence mental health and cognitive decline. Studying them could improve animal welfare in the process.
Lions and tigers and bears: Long-lived zoo animals offer a promising venue to study mental health and neurodegenerative disorders
These animals’ lifestyles often mirror those of people, making them a more relevant milieu than lab mice for determining how environmental factors influence mental health and cognitive decline. Studying them could improve animal welfare in the process.